The uncertain path to the future of imaging biomarkers

Quarterly Journal of Nuclear Medicine and Molecular Imaging

Volumn 51, Issue 2, 2007, Pages 96-98

  Nunn, A D ^a  

^a Bracco Research USA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOGENIC FACTOR; BIOLOGICAL MARKER; FLUORODEOXYGLUCOSE; FLUORODEOXYGLUCOSE F 18; IBRITUMOMAB TIUXETAN; IODINE 131; RADIOPHARMACEUTICAL AGENT; RITUXIMAB; TOSITUMOMAB I 131; TRASTUZUMAB;

ALZHEIMER DISEASE; CANCER; CLINICAL RESEARCH; DRUG APPROVAL; DRUG RESPONSE; DRUG TARGETING; EDITORIAL; HEART MUSCLE PERFUSION; HUMAN; ISOTOPE LABELING; LUNG CANCER; MOLECULAR IMAGING; NONHODGKIN LYMPHOMA; NUCLEAR MEDICINE; POSITRON EMISSION TOMOGRAPHY; PROGNOSIS; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY;

ANIMALS; BIOLOGICAL MARKERS; DRUG DELIVERY SYSTEMS; FORECASTING; HUMANS; MOLECULAR PROBE TECHNIQUES; NUCLEAR MEDICINE; POSITRON-EMISSION TOMOGRAPHY; TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON;

EID: 34447498529     PISSN: 18244785     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Editorial

References (11)

1. Innovation and stagnation. Challenge and opportunity on the critical path to new medical products. FDA. 2004; March, p. 11, 24. Available at: http://www.fda.gov/oc/initiatives/criticalpath/ Accessed July 11, 2005.
2. Critical path opportunities report. FDA March 2006. Available at: http://www.fda.gov/oc/initiatives/criticalpath/ Accessed April 3, 2006.
3. Critical path opportunities list. FDA March 2006. Available at: http://www.fda.gov/oc/initiatives/criticalpath/ Accessed April 3. 2006.
4. Public-private partnership forms The Biomarkers Consortium to advance the science of personalized medicine. October 2006. Available at: http://www.fnih.org/Biomarkers%20Consortium/Biomarkers_home.shtml/ Accessed January 2, 2007.
5. Nunn AD. The cost of developing imaging agents for routine clinical use. Invest Radiol 2006;41:206-12.
6. 18F-FDG PET as a candidate for "qualified biomarker": functional assessment of treatment response in oncology. J Nucl Med 2006;47:901-3.
7. Nuclear medicine usage grows, led by PET. J Nucl Med 2006;47:13N.
8. EANM National Society Statistics Survey 2006. European Association of Nuclear Medicine (EANM). A-1020 Vienna, Hollandstrasse 14/Mezzanine.
9. Stamm-Meyer A, Nosske D, Schnell-Inderst F, Hacker M, Hahn K, Brix G. Diagnostic nuclear medicine procedures in Germany between 1996 and 2002: application frequencies and collective effective doses. Nuklearmedizin 2006;45:1-9.
10. Weissleder R, Ntziachristos V. Shedding light onto live molecular targets. Nat Med 2003;9:123-8.
11. Korpanty G, Carbon JG, Grayburn PA, Fleming JB, Brekken RA. Monitoring response to anticancer therapy by targeting microbubbles to tumor vasculature. Clin Cancer Res 2007;13:323-30.